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Abstract
Aim—To study the eVect of folate treat-
ment on hyperhomocysteinaemia and the
eVect of 5,10-methylenetetrahydrofolate
reductase (MTHFR) gene polymorphism
on total homocysteine and folate concen-
trations after renal transplantation.
Methods—A total of 30 transplanted chil-
dren and adolescents were investigated for
total homocysteine and folate serum con-
centrations before and after folate treat-
ment, as well as for the presence of the
MTHFR C677T polymorphism.
Results—The allele frequency of C677T
polymorphism in the MTHFR gene in the
study population (0.33) was not diVerent
to that in controls (0.38). Before folate
treatment the homocysteine concentra-
tion was raised in all groups; following
folate supplementation it was significantly
decreased in the CC and CT groups, but
not in the TT group. In patients with CC
genotype, serum homocysteine correlated
with serum creatinine and cholesterol,
and time since transplantation before
treatment.
Conclusion—Folate supplementation ap-
pears to be an eVective strategy to nor-
malise total homocysteine concentration
in renal transplanted children and adoles-
cents.
(Arch Dis Child 2001;85:47–49)
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Cardiovascular morbidity in renal transplant
recipients is high and remains the leading cause
of mortality in these patients. Recently, hyper-
homocysteinaemia has been implicated as an
independent risk factor for the development of
arteriosclerotic lesions.1
Serum and total plasma homocysteine con-
centrations are increased in incipient renal fail-
ure and any further decline in renal function.2
Recently, it has been reported that treatment
with cyclosporin A also induces an increase in
homocysteine concentration.3
Supplementation with folate has been shown
to represent a new therapeutic approach for
lowering homocysteine concentration.4 A com-
mon genetic variant C677T of the gene encod-
ing for the enzyme 5,10-methylenetetrahydro-
folate reductase (MTHFR) was recently
described.5 This polymorphism has also been
shown to correlate with raised total plasma
homocysteine concentrations.6
The aims of the present study were there-
fore: (1) to measure total homocysteine
concentration before and after folate treat-
ment; (2) to investigate the prevalence of
C677T MTHFR gene polymorphism; and (3)
to examine the relation between C677T
MTHFR gene polymorphism and the eVect of
folate treatment in kidney transplanted chil-
dren and adolescents.
Patients and methods
Thirty patients (15 girls; age range 9.4–28.1
years; mean (SD) BMI 20.2 (4.4) kg/cm2;
mean (SD) serum creatinine 142 (30) µmol/l)
participated in the study.
Patients had been on haemodialysis for a
mean of 2.5 years (range 0.5–5.5 years) prior to
transplantation. The mean age of the grafts was
5.9 years at the time of study (range 1.1–12.9
years). Basic immunosuppression consisted of
combined cyclosporin A (3.6 (0.8) mg/kg/day,
trough level 100–250 ng/ml) and low dose
(0.12 (0.2) mg/kg/day) methylprednisolone
therapy. Ten patients were on triple therapy,
receiving additional azathioprine (1.8 (0.4)
mg/kg/day). All patients had stable renal func-
tion; no rejection episodes had occurred for at
least six months prior to this study.
Total homocysteine concentrations (free and
protein bound) were determined by fluores-
cence polarisation immunoassay using the
IMX analyser (Abbott Diagnostics Division).
Serum concentrations of folate and vitamin B12
were measured by multiparticular enzyme
immunoassay with the AXSYM analyser (Ab-
bott Diagnostics Division). Blood cyclosporin
A trough concentrations were measured by
radioimmunoassay (Cyclo-Trac, Incstar, Still-
water). After the baseline measurement oral
folate supplementation was started at a dose of
9 mg/day. Following six weeks of supplementa-
tion the same parameters were measured again.
Identification of C677T polymorphism in
the MTHFR gene was performed as described
by Frosst and colleagues.5 One hundred blood
samples from healthy Hungarian subjects were
used as controls.
For statistical analysis the ÷2 test, analysis of
variance, and Pearson’s correlation were per-
formed using the Graphpad Prism 2.01
software package.
The study conformed to the Helsinki decla-
ration and was approved by the local ethics
committee.
Results
The allele frequency of the C677T transition
was 0.33, which is similar to that previously
reported in renal transplant donors (0.34),
recipients (0.35),7 and in our control patients
(0.38). However, the genotype distribution in
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the study group (CC 50%; CT 33.3%; TT
16.6%) was diVerent compared to controls
(CC 66%; CT 30%; TT 4%). In the case of TT
genotype this diVerence was statistically signifi-
cant (p < 0.05).
Within the three groups with diVerent geno-
type there was no significant diVerence in any
of the investigated parameters. MTHFR gene
polymorphism had no influence on graft func-
tion. Genotype distribution was not signifi-
cantly diVerent between subgroups of patients
with diVerent aetiologies for end stage renal
failure.
Table 1 shows serum concentrations of
homocysteine, folate, and vitamin B12 in the
renal transplant patients before and after folate
treatment according to MTHFR C677T geno-
type. Before folate treatment the mean homo-
cysteine concentration was raised in all groups,
whereas the concentration of folate was in the
normal range. Following folate treatment,
folate concentration significantly increased in
all groups, and total homocysteine decreased
significantly in the CC and CT groups. In
patients with TT genotype, total homocysteine
decreased to normal, but this decrease was not
statistically significant. There were no diVer-
ences in vitamin B12 concentration according to
MTHFR genotype or folate treatment. Table 2
shows the prevalence of borderline, moderate,
or severe hyperhomocysteinaemia and border-
line, moderate, or severe deficiency of folate or
vitamin B12.
In renal transplant recipients with CC geno-
type, homocysteine concentration correlated
with serum creatinine (r = 0.77, p < 0.01),
time since transplantation (r = 0.60, p < 0.05),
and serum cholesterol (r = 0.74, p < 0.01)
prior to folate treatment. Following adminis-
tration of folate these correlations were no
longer present. There was no correlation
between serum homocysteine and any param-
eters measured in both groups with the T
allele.
Discussion
In accordance with studies in adult patients,
our results showed an increased homocysteine
concentration children and adolescents who
had undergone transplantation. It is well
known that treatment with folate lowers serum
homocysteine in renal transplant recipients or
patients on dialysis.4 Daily oral administration
of 9 mg folate was highly eVective in correcting
the hyperhomocysteinaemia of our patients.
This supplementation seems to be an eVective
and safe strategy that leads to normalisation of
homocysteine concentration in the majority of
these subjects; this may reduce cardiovascular
morbidity and mortality after renal transplan-
tation.
The metabolic pathway of homocysteine
requires the enzyme MTHFR for conversion of
5,10-methylenetetrahydrofolate to 5-methyl-
tetrahydrofolate, which is the active form of
folate. Recent studies clearly showed that
homozygosity for the C677T transition in the
MTHFR gene of patients on dialysis or after
renal transplantation results in a further
increase of homocysteine concentrations.8
However, the polymorphism of the MTHFR
gene does not seem to be a clinically important
determinant of renal graft survival.7
In our study the allelic frequency of
MTHFR gene polymorphism in renal trans-
plant recipients was comparable to that found
in other investigations,6 and did not diVer from
that in the healthy population. There was no
correlation between primary renal disease and
the MTHFR genotype. We could not show the
influence of MTHFR gene polymorphism on
homocysteine or folate concentrations, al-
though homocysteine concentrations were
slightly higher, and folate concentrations lower
in patients with the T allele. The lack of corre-
lation between homocysteine and folate con-
centrations and MTHFR C to T transition
might be a result of the relatively small number
of patients included in the study. Interestingly,
the percentage of patients with moderate or
severe hyperhomocysteinaemia or folate defi-
ciency did not diVer between the groups with
respect to MTHFR genotype.
Our findings also suggest that MTHFR
polymorphism has no influence on the eVect of
folate administration. The role of impaired
renal function and serum cyclosporin A and
folate concentration as a determinant of
homocysteine concentrations has been previ-
ously confirmed.3 In our study population
there was a significant eVect of serum creati-
nine, cholesterol, and time after transplanta-
tion on homocysteine concentration in renal
graft recipients with CC genotype. In subjects
with one or two mutated alleles there was no
Table 1 Serum concentrations of total homocysteine,
folate, and vitamin B12 in renal transplant recipients
MTHFR C677T
gene polymorphism
Before folate
treatment
After folate
treatment p value
Homocysteine (µmol/l)
CC 16.3 (7.7) 9.7 (3.3) <0.01
CT 20.1 (18.4) 10.3 (3.3) <0.05
TT 19.6 (11.7) 10.8 (4.4) NS
Folate (ng/ml)
CC 8.2 (4.3) 17 (3.6) <0.01
CT 5.3 (4.8) 16.4 (4.8) <0.01
TT 7.8 (3.2) 15 (4.9) <0.05
Vitamin B12 (pg/ml)
CC 388 (187) 402 (202) NS
CT 285 (175) 323 (191) NS
TT 283 (107) 358 (129) NS
Data are presented as mean (SD).
NS, non-significant.
Table 2 Prevalence of no, borderline, moderate, or severe hyperhomocysteinaemia, and
folate and vitamin B12 deficiency in renal transplant recipients
Before treatment After treatment
MTHFR C677T gene
polymorphism No Borderline
Moderate
or severe No Borderline
Moderate
or severe
Homocysteine (µmol/l) <12 12–15 >15 <12 12–15 >15
CC 4 (26.6) 3 (20) 8 (53.3) 12 (80) 1 (6.6) 2 (13.3)
CT 3 (30) 2 (20) 5 (50) 6 (60) 4 (40) 0 (0)
TT 1 (20) 1 (20) 3 (60) 3 (60) 1 (20) 1 (20)
Folate (ng/ml) >5.3 3.7–5.3 <3.7 >5.3 3.7–5.3 <3.7
CC 8 (53.3) 7 (46.6) 0 (0) 15 (100) 0 (0) 0 (0)
CT 2 (20) 2 (20) 6 (60) 9 (90) 1 (10) 0 (0)
TT 3 (60) 2 (40) 0 (0) 5 (100) 0 (0) 0 (0)
Vitamin B12 (pg/ml) >187 157–187 <157 >187 157–187 <157
CC 14 (93.3) 1 (6.6) 0 (0) 15 (100) 0 (0) 0 (0)
CT 6 (60) 3 (30) 1 (10) 10 (100) 0 (0) 0 (0)
TT 4 (80) 0 (0) 1 (20) 5 (100) 0 (0) 0 (0)
Percentages are in brackets.
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correlation between homocysteine concentra-
tion and the observed parameters.
Hyperhomocysteinaemia has been described
as an additional risk factor for cardiovascular
disease in renal transplant patients. This may
be a result of the fact that homocysteine
induces endothelial activation of factor V,
reduces protein C activator production by
arterial and venous endothelial cells, and
induces endothelial cell injury in vitro.
In summary, we believe this to be the first
investigation into homocysteine concentration,
treatment of hyperhomocysteinaemia, and
prevalence of MTHFR polymorphism in renal
transplanted children and adolescents. The
increased total homocysteine in our patients
was reduced by oral folate administration.
MTHFR genotype had no significant influence
on the treatment of hyperhomocysteinaemia.
Based on these results, folate supplementation
appears to be an eVective strategy for normali-
sation of total homocysteine concentrations in
renal transplanted children and adolescents.
Parts of the study were supported by the OTKA F 029782/
029779 and FKFP 0134/01, ETT 157-299/200, and OMFB
TeT 5/98. Attila J Szabo is a research fellow, supported by the
Magyary postdoctorial fellowship.
1 Stampfer MJ, Malinow MR, Willet WC, et al. A prospective
study of plasma homocyst(e)ine and risk of myocardial inf-
arction in US physicians. JAMA 1992;268:877–81.
2 Soria C, Chadefaux B, Coude M, et al. Concentrations of
total homocysteine in plasma in chronic renal failure. Clin
Chem 1990;36:2137–8.
3 Armadottir M, Hultberg B, Vladov V, et al. Hyperhomo-
cysteinemia in cyclosporione-treated renal transplant
recipients. Transplantation 1996;61:509–12.
4 Schröder CH, de Boer AW, Giesen AM, et al. Treatment of
hyperhomocysteinemia in children on dialysis by folic acid.
Pediatr Nephrol 1999;13:583–5.
5 Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk
factor for vascular disease: a common mutation in methyl-
enetetrahydrofolate reductase. Nat Genet 1995;10:111–13.
6 Födinger M, Wölfl G, Fischer G, et al. EVect of MTHFR
677C>T on plasma total homocysteine levels in renal graft
recipients. Kidney Int 1999;55:1072–80.
7 Liangos O, Kreutz R, Beige J, et al. Methylenetetrahydrofolate-
reductase gene C677T variant and kidney-transplant
survival. Nephrol Dial Transplant 1998;13:2351–4.
8 Födinfer M, Mannhalter C, Wölfl G, et al. Mutation (677 C
to T) in the methylenetetrahydrofolate reductase gene
aggravates hyperhomocysteinemia in hemodialysis pa-
tients. Kidney Int 1997;52:517–23.
Hyperhomocysteinaemia in renal transplant recipients 49
www.archdischild.com
